R7E Stock Overview
A clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Cybin Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$9.79 |
| 52 Week High | US$25.65 |
| 52 Week Low | US$6.16 |
| Beta | 0.91 |
| 11 Month Change | 57.48% |
| 3 Month Change | -3.58% |
| 1 Year Change | -45.18% |
| 33 Year Change | -84.48% |
| 5 Year Change | n/a |
| Change since IPO | -84.85% |
Recent News & Updates
Recent updates
Shareholder Returns
| R7E | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 18.4% | 3.7% | 1.1% |
| 1Y | -45.2% | -7.6% | 18.9% |
Return vs Industry: R7E underperformed the German Pharmaceuticals industry which returned -7.6% over the past year.
Return vs Market: R7E underperformed the German Market which returned 18.9% over the past year.
Price Volatility
| R7E volatility | |
|---|---|
| R7E Average Weekly Movement | 17.6% |
| Pharmaceuticals Industry Average Movement | 8.1% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: R7E's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: R7E's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 50 | Doug Drysdale | www.cybin.com |
Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company’s development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds. The company has research and collaboration agreement with TMS Neurohealth Centers Inc. for development of psychedelic compound-based therapeutics; Kernel for use of Kernel flow technology to measure neural activity; and Greenbook TMS to establish mental health centers.
Cybin Inc. Fundamentals Summary
| R7E fundamental statistics | |
|---|---|
| Market cap | €213.76m |
| Earnings (TTM) | -€52.26m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-4.1x
P/E RatioIs R7E overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| R7E income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$78.39m |
| Earnings | -CA$78.39m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.85 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did R7E perform over the long term?
See historical performance and comparison